Alectos Therapeutics Inc.
$250,000.00 CAD
≈ 3 Canadians' average pay for a year
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2021-2022
- Agreement period
- October 15, 2021 – June 30, 2022
- Reference
- nrc-cnrc:172-2021-2022-Q3-981188
Published purpose
The project will characterize and validate novel small molecule glucocerebrosidase 2 inhibitors as disease-modifying therapeutics for Parkinson’s disease.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported July 30, 2026 from open.canada.ca Grants & Contributions